Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunogenomic Landscape of Hematological Malignancies.
Dufva O, Pölönen P, Brück O, Keränen MAI, Klievink J, Mehtonen J, Huuhtanen J, Kumar A, Malani D, Siitonen S, Kankainen M, Ghimire B, Lahtela J, Mattila P, Vähä-Koskela M, Wennerberg K, Granberg K, Leivonen SK, Meriranta L, Heckman C, Leppä S, Nykter M, Lohi O, Heinäniemi M, Mustjoki S. Dufva O, et al. Among authors: kankainen m. Cancer Cell. 2020 Sep 14;38(3):424-428. doi: 10.1016/j.ccell.2020.08.019. Cancer Cell. 2020. PMID: 32931743 No abstract available.
Understanding human health through metatranscriptomics.
Ojala T, Kankuri E, Kankainen M. Ojala T, et al. Among authors: kankainen m. Trends Mol Med. 2023 May;29(5):376-389. doi: 10.1016/j.molmed.2023.02.002. Epub 2023 Feb 25. Trends Mol Med. 2023. PMID: 36842848 Free article. Review.
Altered acylcarnitine metabolism and inflexible mitochondrial fuel utilization characterize the loss of neonatal myocardial regeneration capacity.
Kankuri E, Finckenberg P, Leinonen J, Tarkia M, Björk S, Purhonen J, Kallijärvi J, Kankainen M, Soliymani R, Lalowski M, Mervaala E. Kankuri E, et al. Among authors: kankainen m. Exp Mol Med. 2023 Apr;55(4):806-817. doi: 10.1038/s12276-023-00967-5. Epub 2023 Apr 3. Exp Mol Med. 2023. PMID: 37009793 Free PMC article.
Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity.
Dufva O, Koski J, Maliniemi P, Ianevski A, Klievink J, Leitner J, Pölönen P, Hohtari H, Saeed K, Hannunen T, Ellonen P, Steinberger P, Kankainen M, Aittokallio T, Keränen MAI, Korhonen M, Mustjoki S. Dufva O, et al. Among authors: kankainen m. Blood. 2020 Feb 27;135(9):597-609. doi: 10.1182/blood.2019002121. Blood. 2020. PMID: 31830245 Free PMC article.
Immunogenomic Landscape of Hematological Malignancies.
Dufva O, Pölönen P, Brück O, Keränen MAI, Klievink J, Mehtonen J, Huuhtanen J, Kumar A, Malani D, Siitonen S, Kankainen M, Ghimire B, Lahtela J, Mattila P, Vähä-Koskela M, Wennerberg K, Granberg K, Leivonen SK, Meriranta L, Heckman C, Leppä S, Nykter M, Lohi O, Heinäniemi M, Mustjoki S. Dufva O, et al. Among authors: kankainen m. Cancer Cell. 2020 Sep 14;38(3):380-399.e13. doi: 10.1016/j.ccell.2020.06.002. Epub 2020 Jul 9. Cancer Cell. 2020. PMID: 32649887 Free article.
KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia.
Malani D, Yadav B, Kumar A, Potdar S, Kontro M, Kankainen M, Javarappa KK, Porkka K, Wolf M, Aittokallio T, Wennerberg K, Heckman CA, Murumägi A, Kallioniemi O. Malani D, et al. Among authors: kankainen m. Leukemia. 2020 Oct;34(10):2780-2784. doi: 10.1038/s41375-020-0978-7. Epub 2020 Jul 17. Leukemia. 2020. PMID: 32678289 No abstract available.
RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses.
Adnan Awad S, Dufva O, Ianevski A, Ghimire B, Koski J, Maliniemi P, Thomson D, Schreiber A, Heckman CA, Koskenvesa P, Korhonen M, Porkka K, Branford S, Aittokallio T, Kankainen M, Mustjoki S. Adnan Awad S, et al. Among authors: kankainen m. Leukemia. 2021 Apr;35(4):1087-1099. doi: 10.1038/s41375-020-01011-5. Epub 2020 Aug 11. Leukemia. 2021. PMID: 32782381 Free PMC article.
93 results